Pharmacyclics, Inc. is a United States-based biopharmaceutical company engaged in developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company designs, develops and commercializes therapies intended to improve quality of life, increase duration of life and resolve unmet medical healthcare needs of the patients. The Company also identifies and controls product candidates based on scientific development and administrational expertise. On November 13, 2013, the United States Food and Drug Administration approved IMBRUVICATM under accelerated approval as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL). On November 13, 2013, the Company launched, developed, and commercialized its first product, IMBRUVICATM in the United States. In addition to IMBRUVICATM, the Company has three other product candidates in clinical development and other preclinical molecules in lead optimization.